News | Ventricular Assist Devices (VAD) | June 11, 2015

ECRI Institute Review Supports Impella RP Device

Overview of published articles indicates significant improvement in hemodynamics with high short- and long-term survival rates

ECRI Institute, review, Impella RP, Abiomed

June 11, 2015 - ECRI Institute recently reviewed published data on Abiomed's Impella RP (Right Percutaneous) transcatheter ventricular assist device (VAD). The institute said the device provides immediate significant improvements in hemodynamics with considerable short-term and long-term survival rates.

The Impella RP is a catheter-based intracardiac microaxial blood pump to support short-term pulmonary circulation in pediatric or adult patients. It is intended to provide percutaneous circulatory support to restore normal right heart hemodynamics, reduce right ventricular work, and enable the right heart to potentially recover or sustain the patient until the next therapy.

ECRI searched PubMed, EMBASE and selected Web-based resources for relevant documents published between Jan. 1, 2010, and April 30, 2015. The healthcare technology research firm identified two small nonrandomized comparison studies and three small cohort studies (two of which were retrospective) reporting on 138 patients.

Review of the abstracts of published articles suggests that Impella RP provides immediate significant improvements in hemodynamics with short-term (30 days) and long-term (1 year) survival rates of approximately 70 and 50 percent, respectively. Study populations were small and consisted of mostly male adults with acute right heart failure. Only one study reported on adverse events.

ECRI was unable to determine whether Impella RP works better than similar right ventricular assist devices (e.g., Excor Pediatric VAD, Percutaneous ventricular assist device [PVAD]/implantable ventricular assist device [IVAD] or CentriMag right ventricular assist device [RVAD]) because no studies were available that compare the devices.

The ECRI Institute is an independent nonprofit organization that conducts research into the most effective approaches for improving patient care.  

For more information:

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Videos | Heart Failure | March 23, 2018
David Lanfear M.D., FACC, head of advanced heart failure and cardiac transplantation, Henry Ford Hospital, Detroit, d
Overlay Init